Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials
- PMID: 24457345
- PMCID: PMC3982838
- DOI: 10.1093/cid/ciu046
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials
Abstract
Background: Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.
Methods: A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study quality was rated using the Cochrane risk-of-bias tool.
Results: Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-daily subgroups, although the association with adherence in the once-daily subgroup was not statistically significant. The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean difference = 2.55%; 95% confidence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve virological suppression more frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to 1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.
Conclusions: Lower pill burden was associated with both better adherence and virological suppression. Adherence, but not virological suppression, was slightly better with once- vs twice-daily regimens.
Keywords: ART; fixed-dose combination; once-daily; randomized controlled trials; twice-daily.
Figures




Comment in
-
[Antiretroviral treatment regimens: less tablets for a better result].Med Mal Infect. 2014 Sep;44(9):445-6. doi: 10.1016/j.medmal.2014.07.009. Med Mal Infect. 2014. PMID: 25392874 French. No abstract available.
Similar articles
-
Once-daily dosing of nevirapine in HAART.J Antimicrob Chemother. 2008 Jan;61(1):13-6. doi: 10.1093/jac/dkm432. Epub 2007 Nov 14. J Antimicrob Chemother. 2008. PMID: 18006524
-
Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.Int J STD AIDS. 2012 May;23(5):351-5. doi: 10.1258/ijsa.2011.011292. Int J STD AIDS. 2012. PMID: 22648890 Free PMC article.
-
Comparison of adherence rates for antiretroviral, blood pressure, or mental health medications for HIV-positive patients at an academic medical center outpatient pharmacy.J Manag Care Spec Pharm. 2014 Aug;20(8):809-14. doi: 10.18553/jmcp.2014.20.8.809. J Manag Care Spec Pharm. 2014. PMID: 25062074 Free PMC article.
-
Does once-daily etravirine have a role in the management of HIV-1 infection?Drugs. 2013 Mar;73(3):207-12. doi: 10.1007/s40265-013-0022-6. Drugs. 2013. PMID: 23420097 Review.
-
Efficacy and safety of once-daily regimens in the treatment of HIV infection.Drugs. 2008;68(5):567-78. doi: 10.2165/00003495-200868050-00001. Drugs. 2008. PMID: 18370438 Review.
Cited by
-
The management of treatment-experienced HIV patients (including virologic failure and switches).Ther Adv Infect Dis. 2020 Jan 20;7:2049936120901395. doi: 10.1177/2049936120901395. eCollection 2020 Jan-Dec. Ther Adv Infect Dis. 2020. PMID: 32010443 Free PMC article. Review.
-
Psychosocial interventions enhance HIV medication adherence: A systematic review and meta-analysis.J Health Psychol. 2020 Sep;25(10-11):1326-1340. doi: 10.1177/1359105318755545. Epub 2018 Feb 8. J Health Psychol. 2020. PMID: 29417851 Free PMC article.
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5. Infection. 2017. PMID: 28477212
-
Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.AIDS Behav. 2019 May;23(5):1250-1257. doi: 10.1007/s10461-018-2271-6. AIDS Behav. 2019. PMID: 30284081 Free PMC article.
-
Real-world Rollout of Injectable Antiretrovirals for HIV Prevention and Treatment: Correlates of Early Adoption.Open Forum Infect Dis. 2025 Jan 20;12(2):ofaf029. doi: 10.1093/ofid/ofaf029. eCollection 2025 Feb. Open Forum Infect Dis. 2025. PMID: 40207202 Free PMC article.
References
-
- Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3. - PubMed
-
- Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73. - PubMed
-
- Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med. 2003;139:810–6. - PubMed
-
- Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med. 2006;354:251–60. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous